Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOV-1776
- Development stage
- Phase 1
- Lead developer
- Novilla
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
NOV-1776 is a topically applied, transcutaneous gel formulation of the nonsteroidal anti-inflammatory drug ketorolac tromethamine at 12.5% w/w, developed to provide systemic and local analgesic and anti-inflammatory effects via skin application rather than injection. It is being evaluated in Phase 1 clinical studies as an alternative to intravenous ketorolac tromethamine, with goals of achieving comparable exposure and pain control while improving convenience and potentially reducing systemic adverse effects associated with parenteral NSAID use, including for acute gout flares.[1][3][5][7]
- Other names
- transcutaneous ketorolac tromethamine gel 12.5%
Beyond the preview
Go deeper on NOV-1776.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOV-1776.